Simon Lowry compensation by year
Emergent BioSolutions Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $545,002 |
| Bonus | $0 |
| Stock awards | $362,500 |
| Option awards | $263,606 |
| Non-equity incentive | $289,668 |
| Pension and deferred compensation | $0 |
| All other | $10,500 |
| Total | $1,471,276 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Emergent BioSolutions Inc. DEF 14A filed March 20, 2026, accession 0001367644-26-000033, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 62,500 | $772,500 | — |
| RSU | 19,654 | $242,923 | — |
| Option | 27,012 | — | $8.48 |
| Option | 62,500 | — | $5.80 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Emergent BioSolutions Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed March 20, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-04-29 | Grant or award | — | 100,111 | $0.00 | 177,914 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Emergent BioSolutions discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,635,005 | $1,582,560 | $90,460 | $3,308,025 |
| Involuntary termination without cause | $1,021,878 | $52,330 | $56,537 | $1,130,745 |
Per the Potential Payments Upon Termination or Change in Control table in Emergent BioSolutions Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Emergent BioSolutions’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joseph Papa | President, Chief Executive Officer and Director | $5,321,147 |
| Richard Lindahl | Executive Vice President, Chief Financial Officer | $2,708,723 |
| Coleen Glessner | Executive Vice President, Quality and Ethics and Compliance | $1,664,258 |
| Simon Lowry · this page | Chief Medical Officer, Head of Research and Development | $1,471,276 |
| Paul Williams | Senior Vice President, Products Business | $1,391,158 |
The full Emergent BioSolutions compensation record
free company briefThis page is one person within Emergent BioSolutions's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Emergent BioSolutions's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Emergent BioSolutions's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat